![Astrid Hilde Myrset](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Astrid Hilde Myrset
Corporate Officer/Principal chez
AlgiPharma Holding AS
Profil
Astrid Hilde Myrset is currently the Director of Clinical & Preclinical at AlgiPharma Holding AS.
Previously, she worked as a Director at Omegatri AS and as a Principal at both GE Healthcare AS and GE Healthcare Ltd.
Postes actifs de Astrid Hilde Myrset
| Sociétés | Poste | Début |
|---|---|---|
AlgiPharma Holding AS
 AlgiPharma Holding AS AlgiPharma Holding AS is a privately owned, Norwegian clinical-stage biopharmaceutical company that specializes in developing proprietary alginate oligosaccharide technology derived from brown seaweed. The company is based in Sandvika, Norway. The company’s platform produces highly purified, GMP-compliant oligosaccharides with properties such as water solubility, stability, non-toxicity, and biocompatibility. This technology is used as a drug delivery platform and as standalone active pharmaceutical ingredients targeting diseases including cystic fibrosis, COPD, infectious diseases, and wound healing. The oligosaccharides help release stagnant mucus, disrupt microbial biofilms, inhibit microbial adherence and virulence, prevent fungal tissue invasion, and enhance therapeutic delivery and efficacy. The technology can also be conjugated with antimicrobials to reduce toxicity without inducing microbial resistance. AlgiPharma has completed six clinical trials for its lead drug candidate targeting cystic fibrosis and maintains a comprehensive preclinical toxicology portfolio supporting multiple formulations for inhalation, oral, intravenous, and topical administration. | Corporate Officer/Principal | - |
Anciens postes connus de Astrid Hilde Myrset
| Sociétés | Poste | Fin |
|---|---|---|
GE Healthcare AS
 GE Healthcare AS Medical SpecialtiesHealth Technology Specializes in medical imaging services | Corporate Officer/Principal | - |
GE Healthcare Ltd. (United Kingdom)
 GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology Provides transformational medical technologies and services | Corporate Officer/Principal | - |
Omegatri AS
 Omegatri AS Food: Specialty/CandyConsumer Non-Durables Develops tablets and powders containing Omega-3 for the health and food industry | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
1
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
GE Healthcare AS
GE Healthcare AS Medical SpecialtiesHealth Technology Specializes in medical imaging services | Health Technology |
GE Healthcare Ltd. (United Kingdom)
GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology Provides transformational medical technologies and services | Health Technology |
Omegatri AS
Omegatri AS Food: Specialty/CandyConsumer Non-Durables Develops tablets and powders containing Omega-3 for the health and food industry | Consumer Non-Durables |
AlgiPharma Holding AS
AlgiPharma Holding AS AlgiPharma Holding AS is a privately owned, Norwegian clinical-stage biopharmaceutical company that specializes in developing proprietary alginate oligosaccharide technology derived from brown seaweed. The company is based in Sandvika, Norway. The company’s platform produces highly purified, GMP-compliant oligosaccharides with properties such as water solubility, stability, non-toxicity, and biocompatibility. This technology is used as a drug delivery platform and as standalone active pharmaceutical ingredients targeting diseases including cystic fibrosis, COPD, infectious diseases, and wound healing. The oligosaccharides help release stagnant mucus, disrupt microbial biofilms, inhibit microbial adherence and virulence, prevent fungal tissue invasion, and enhance therapeutic delivery and efficacy. The technology can also be conjugated with antimicrobials to reduce toxicity without inducing microbial resistance. AlgiPharma has completed six clinical trials for its lead drug candidate targeting cystic fibrosis and maintains a comprehensive preclinical toxicology portfolio supporting multiple formulations for inhalation, oral, intravenous, and topical administration. |
Choisissez Zonebourse 
